ClinicalTrials.gg
RecruitingNCT07227012Updated Oct 8, 2026

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

A Phase 1/2 interventional study of PF-08634404 and Ipilimumab in Carcinoma, Hepatocellular, Hepatocellular Cancer and Hepatocellular Carcinoma, sponsored by Pfizer. Recruiting at 60 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 8, 2026First site in ChinaSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Carcinoma, Hepatocellular by Pfizer — 2 open to participants now, 2 under way, none of them phase 3. Carcinoma, Hepatocellular · Pfizer.

Planned enrollment
6th of 12
138 · median 113
Started
2025
the only one that year
Phase 1/2
Only one
of the 12
Registered
12th of 12
by date

Among the 12 studies in Carcinoma, Hepatocellular by Pfizer, this one is the 6th largest by planned enrollment, is the only one that started in 2025, is the only one in phase 1/2, and was the 12th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

2 of the 12 studies in Carcinoma, Hepatocellular by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Carcinoma, Hepatocellular by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body.

To join the study, participants must meet the following conditions:

  • Be 18 years or older.
  • Have locally advanced or metastatic HCC.
  • Is not a candidate for complete surgical or loco-regional therapies.
  • Have not received any whole-body treatment for HCC.

Participants will receive PF-08634404 either alone or in combination with ipilimumab. The medicine will be given through intravenous (IV) infusions, which means it will be administered directly into a vein. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.

03

Conditions studied

  • Carcinoma, Hepatocellular
  • Hepatocellular Cancer
  • Hepatocellular Carcinoma
  • Unresectable Hepatocellular Carcinoma
  • Liver Neoplasms
  • Advanced Hepatocellular Carcinoma
  • Metastatic Hepatocellular Carcinoma

Keywords

  • Hepatocellular Carcinoma
  • Liver cancer
  • Liver Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • 18 years of age or older at screening.
  • Locally advanced or HCC with diagnosis confirmed by histology/cytology or clinically by AASLD criteria (for patients with cirrhosis). Participants without cirrhosis require histological confirmation of diagnosis.
  • Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies.
  • At least 1 measurable (as defined by 1.1 per investigator) and untreated lesion.
  • Adequate hepatic, liver, and renal function
  • No prior systemic therapy for HCC.
  • performance status 0 or 1
  • Class A

Key Exclusion Criteria:

  • Moderate or severe ascites.
  • History of hepatic encephalopathy.
  • Participants with known active CNS lesions, including , brainstem, meningeal, or spinal cord metastases or compression.
  • risk of hemorrhage or fistula.
  • Participants with any history of another within 3 years.
  • History of allogeneic organ transplantation and hematopoietic stem cell transplantation.
  • Participants with active diseases requiring systemic treatment within the past 2 years.
  • Clinically significant cardiovascular disease within 6 months prior to the first dose.
  • Major surgery or severe trauma within 4 weeks prior to the first dose or planned major surgery during the study.
  • History of severe bleeding tendency or coagulation dysfunction.
  • History of severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding, including bleeding event due to esophageal and/or gastric varices, within 6 months prior to the first dose.
  • Participants with acute, chronic or symptomatic infections.
  • Participants with history of immunodeficiency.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
138 participants (estimated)

Study arms

  • Experimental
    Phase 1b

    Participants will be allocated to sequential dose levels of PF-08634404 and ipilimumab.

    Biological: PF-08634404 · Biological: Ipilimumab

  • Experimental
    Phase 2

    Participants will be randomized to receive either PF-08634404 monotherapy or PF-08634404 combined with ipilimumab.

    Biological: PF-08634404 · Biological: Ipilimumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.

    Time frame: Through end of study and up to approximately 24 months

  2. Phase 1b: Number of participants with Dose limiting toxicities (DLT)

    DLTs are a predefined set of adverse events that are at least possibly related to any or all of the study interventions. The number of participants who experienced DLTs during the DLT observation period.

    Time frame: Through 90 days after the last dose of study intervention; Approximately 24 months

  3. Phase 2: Confirmed Overall Response Rate (ORR) using RECIST 1.1 as assessed by investigator

    ORR is the proportion of participants with a best overall response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 by investigator.

    Time frame: Approximately 24 months

  4. Phase 2: Recommended dose of PF-08634404 in combination with ipilimumab

    The doses of PF-08634404 and ipilimumab selected to be used in combination based on safety, tolerability, pharmacokinetics, and initial anti-tumor efficacy from Phase 2.

    Time frame: Approximately 24 months

Secondary outcomes

  1. Phase 1b: Confirmed Objective Response Rate (ORR) using RECIST 1.1 as assessed by investigator

    ORR is the proportion of participants with a best overall response of confirmed Complete Response (CR) or confirmed Partial Response (PR) per RECIST 1.1 by investigator.

    Time frame: Approximately 24 months

  2. Duration of Response (DOR) per RECIST 1.1 by investigator

    DOR is the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first.

    Time frame: Approximately 24 months

  3. Progression Free Survival (PFS) per RECIST 1.1 by investigator

    PFS is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first.

    Time frame: Approximately 24 months

  4. Overall Survival (OS)

    OS is defined as the time from the date of first dose to the date of death due to any cause.

    Time frame: Approximately 24 months

  5. Number of Participants With Clinical Laboratory Abnormalities

    Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing

    Time frame: Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (assessed up to approximately 24 months)

  6. Pharmacokinetics (PK): Serum concentrations of PF-08634404

    Predose and/or postdose concentrations of PF-08634404 in combination with ipilimumab.

    Time frame: Up to 24 months

  7. Incidence of antidrug antibody against PF-08634404

    To evaluate immunogenicity of PF-08634404 in combination with ipilimumab.

    Time frame: Up to 24 months

07

Study locations

60 of 60 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Oct 2027, 22 months after the start.

Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's planned 22 months is below that.

Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2025
First posted
Nov 12, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Oct 18, 2027
CompletionEst.
Oct 17, 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added — first site in China. Virginia Mason Medical Center is now Recruiting
Show 6 added (5 United States, 1 China)
  • START Los Angeles, LLC · Los Angeles, United States
  • LACN Century City · Los Angeles, United States
  • University Hospitals Cleveland Medical Center · Cleveland, United States
  • Zhongshan Hospital,Fudan University · Shanghai, China
  • AHN Allegheny General Hospital · Pittsburgh, United States
  • AHN Cancer Institute at Allegheny General Hospital · Pittsburgh, United States
across 2 updates, Sep 28, 2026 – Oct 8, 2026
Show all 2 updates
  1. Oct 8, 2026
    2 sites added
    Show 2 added (2 United States)
    • AHN Allegheny General Hospital · Pittsburgh, United States
    • AHN Cancer Institute at Allegheny General Hospital · Pittsburgh, United States
    + 1 other change: verification date
  2. Sep 28, 2026
    4 sites added — first site in China. Virginia Mason Medical Center is now Recruiting
    Show 4 added (3 United States, 1 China)
    • START Los Angeles, LLC · Los Angeles, United States
    • LACN Century City · Los Angeles, United States
    • University Hospitals Cleveland Medical Center · Cleveland, United States
    • Zhongshan Hospital,Fudan University · Shanghai, China
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07227012
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 12, 2025
Start date
Dec 1, 2025
Primary completion
Oct 18, 2027 (estimated)
Completion
Oct 17, 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404

Start the discussion